EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases

Bo-Shi Zhang iD, Xiao-Meng Zhang, Masaaki Ito, Satoshi Yajima, Kimihiko Yoshida, Mikiko Ohno, Eiichiro Nishi, Hao Wang iD, Shu-Yang Li, Masaaki Kubota, Yoichi Yoshida, Tomoo Matsutani und 12 weitere

International Journal of Molecular Sciences · 30.04.2024 · 25 (9) · 4935

DOI: 10.3390/ijms25094935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.04.2024. Verfasst von Bo-Shi Zhang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. Hauptthemen laut MEDLINE: Autoantibodies, Biomarkers, Inflammation, Jumonji Domain-Containing Histone Demethylases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesBiomarkersInflammationJumonji Domain-Containing Histone DemethylasesHumansFemaleMaleMiddle AgedNeoplasmsAgedAdultDiabetes Mellitus

Stichwörter der Autor:innen

JMJD6acute myocardial infarctionatherosclerosisautoantibodydiabetes mellitusesophageal cancerinflammationischemic stroke

Substanzen

AutoantibodiesBiomarkersJMJD6 protein, humanJumonji Domain-Containing Histone Demethylases

Autor:innen und Institutionen

  • Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
  • Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
  • Department of Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 143-8541, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Toho University, Tokyo 143-8541, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
  • Department of Pharmacology, Shiga University of Medical Science, Otsu 520-2192, Japan.

ORCID-Profile: Bo-Shi Zhang, Hao Wang

Förderung

  • Japan Science and Technology Agency
  • Japan Society for the Promotion of Science
  • JSPS KAKENHI

Zitieren

APA

Zhang, B. S., Zhang, X. M., Ito, M., Yajima, S., Yoshida, K., Ohno, M., Nishi, E., Wang, H., Li, S. Y., Kubota, M., Yoshida, Y., Matsutani, T., Mine, S., Machida, T., Takemoto, M., Yamagata, H., Hayashi, A., Yokote, K., Kobayashi, Y., …, & Hiwasa, T. (2024). JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases. International Journal of Molecular Sciences, 25(9), 4935. https://doi.org/10.3390/ijms25094935

Vancouver

Zhang BS, Zhang XM, Ito M, Yajima S, Yoshida K, Ohno M, et al. JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases. International Journal of Molecular Sciences. 2024;25(9):4935. doi:10.3390/ijms25094935

BibTeX
@article{Zhang2024,
  author = {Zhang, Bo-Shi and Zhang, Xiao-Meng and Ito, Masaaki and Yajima, Satoshi and Yoshida, Kimihiko and Ohno, Mikiko and Nishi, Eiichiro and Wang, Hao and Li, Shu-Yang and Kubota, Masaaki and Yoshida, Yoichi and Matsutani, Tomoo and Mine, Seiichiro and Machida, Toshio and Takemoto, Minoru and Yamagata, Hiroki and Hayashi, Aiko and Yokote, Koutaro and Kobayashi, Yoshio and Takizawa, Hirotaka and Kuroda, Hideyuki and Shimada, Hideaki and Iwadate, Yasuo and Hiwasa, Takaki},
  title = {JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {9},
  pages = {4935},
  doi = {10.3390/ijms25094935}
}
Kostenlos starten →